...
首页> 外文期刊>Acta oncologica. >Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact
【24h】

Hyponatremia associates with poor outcome in metastatic renal cell carcinoma patients treated with everolimus: prognostic impact

机译:低血管血症伴有血尿症治疗的转移性肾细胞癌患者的差异:预后影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The prognostication of metastatic renal cell carcinoma (mRCC) is based on Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk classifications. Research has shown that hyponatremia is associated with worse prognosis in cancer. We analyzed the association of hyponatremia and outcome in everolimus-treated mRCC patients.Patients and methods: Baseline and on-treatment (<12 weeks) sodium in 233 mRCC patients was analyzed using Kaplan-Meier, Cox regression and logistic regression. Baseline sodium was correlated with baseline thrombocyte and neutrophil values.Results: 65 (28%) and 41 (18%) patients had sodium < lower limit of normal (LLN) at baseline and on-treatment, respectively. Baseline sodium < LLN was associated with shorter overall survival (OS) (6.1 vs. 10.3 months; p<.001) and progression-free survival (PFS) (2.8 vs. 3.5 months; p — .O4). On-treatment sodium < LLN was associated with shorter OS (5.4 vs. 9.9 months; p< .001) and PFS (2.8 vs. 4.0 months; p<.001). In multivariate analyses adjusted for IMDC factors, baseline and on-treatment sodium < LLN were significantly associated with shorter OS (adjusted HR 1.46 (95% Cl 1.04-2.05); p — .02; adjusted HR 1.80 (95% Cl 1.23-2.61); p = .002; respectively). On-treatment sodium < LLN was significantly associated with progressive disease (OR 0.23 (95% Cl 0.10-0.56); p = .001). A landmark analysis demonstrated that on-treatment hyponatremia was significantly associated with shorter OS and PFS (p = .01 and p = .03, respectively). On-treatment normalization of hyponatremia was associated with improved OS (unadjusted HR 0.61 (95% Cl 0.35-0.98); p — .04), as compared to patients with sustained hyponatremia throughout follow-up.Conclusions: Hyponatremia associates with poor outcome in mRCC patients treated with everolimus. On-treatment normalization of hyponatremia to normal sodium values associates with favorable outcome.
机译:背景:转移性肾细胞癌(MRCC)的预后基于纪念斯隆kettering癌症中心(MSKCC)和国际转移性肾细胞癌数据库联盟(IMDC)风险分类。研究表明,低钠血症与癌症预后的更差有关。我们分析了everolimus治疗的MRCC患者的低钠血症和结果的关联。使用Kaplan-Meier,Cox回归和后勤回归分析了233例MRCC患者的基线和治疗(<12周)钠。基线钠与基线血小板和中性粒细胞值相关。结果:65(28%)和41名(18%)患者分别在基线和接受治疗时具有钠<下限的正常(LLN)。基线钠

著录项

  • 来源
    《Acta oncologica.》 |2018年第11期|共6页
  • 作者

    P. Penttila; P. Bono;

  • 作者单位

    Comprehensive Cancer Center Helsinki University Hospital Helsinki Finland;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号